Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

55.65 -1.63 (-2.85%)
Streaming Delayed Price Updated: 1:58 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session ↗
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
News headline image
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
News headline image
AnaptysBio Announces Participation in Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗
 
Via Benzinga
News headline image
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients ↗
 
Via Benzinga
News headline image
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for AnaptysBio ↗
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
AnaptysBio to Participate in Upcoming November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial ↗
 
Via Benzinga
News headline image
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle ↗
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.